Price T Rowe Associates Inc Kezar Life Sciences, Inc. Transaction History

Price T Rowe Associates Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.6 - $0.92 $21,555 - $33,051	35,926 Added 75.36%	83,600 $51,000
Q1 2024 May 15, 2024	BUY	$0.8 - $1.05 $1,061 - $1,393	1,327 Added 2.86%	47,674 $43,000
Q3 2023 Nov 14, 2023	BUY	$1.08 - $2.54 $20,196 - $47,498	18,700 Added 67.64%	46,347 $56,000
Q2 2023 Aug 14, 2023	BUY	$2.31 - $3.06 $4,631 - $6,135	2,005 Added 7.82%	27,647 $68,000
Q1 2023 May 15, 2023	BUY	$3.13 - $7.31 $3,086 - $7,207	986 Added 4.0%	25,642 $81,000
Q4 2022 Feb 14, 2023	BUY	$6.39 - $8.8 $4,460 - $6,142	698 Added 2.91%	24,656 $174,000
Q3 2022 Nov 14, 2022	BUY	$7.99 - $10.75 $68,881 - $92,675	8,621 Added 56.21%	23,958 $207,000
Q2 2022 Aug 15, 2022	BUY	$4.58 - $17.13 $70,243 - $262,722	15,337 New	15,337 $127,000

38.4M

13.8K

600

Ticker KZR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,369,504
Market Cap $446M
Description
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.